CompletedNCT06256367
Cariprazine and bipolar I symptoms in adults
About this title
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder
Read the official source — NCT06256367Observational studyAges 18+United States + CanadaBipolarity
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 18 more locationsSee all locations and recruitment
Study information
Study start dateStarted: April 18, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Locations
- United States, Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT06256367
- Official title
Show the full official title
Cariprazine Real-world Use in Bipolar I Disorder: Effectiveness, Functioning, Quality of Life, and Tolerability
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham, United States · Beverly Hills, United States · Sacramento, United States
16 more locations
- Cromwell, United States
- Atlanta, United States
- Omaha, United States
- Avon Lake, United States
- Middleburg Heights, United States
- Oklahoma City, United States
- Eugene, United States
- Dallas, United States
- Chatham, Canada
- Kitchener, Canada
- Mississauga, Canada
- Newmarket, Canada
- Toronto, Canada
- Montreal, Canada
- Sherbrooke, Canada
- Verdun, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AbbVie.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
